查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961203

缺血性心臟疾病治療市場－全球產業規模、佔有率、趨勢、機會、預測：依疾病類別、藥物類別、地區和競爭格局分類，2021-2031年

Ischemic Heart Disease Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Class, By Drug Class, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球缺血性心臟疾病(IHD) 治療市場預計將從 2025 年的 62.3 億美元成長到 2031 年的 79.8 億美元，複合年成長率為 4.21%。

這些藥物對於治療心肌供血受限的疾病至關重要，例如心肌梗塞和心絞痛。市場成長的主要促進因素是全球人口老化以及文明病相關合併症（包括肥胖和糖尿病）的日益普遍，這些疾病都需要長期藥物治療。根據美國心臟學會 (ACC) 2023 年的數據，缺血性心臟疾病影響著全球約 2.4 億人，這使得國際市場對有效治療性介入的需求持續迫切。

市場概覽
預測期 2027-2031
市場規模：2025年 62.3億美元
市場規模：2031年 79.8億美元
複合年成長率：2026-2031年 4.21%
成長最快的細分市場 心絞痛
最大的市場 北美洲

阻礙市場擴張的一大障礙是重磅藥物專利到期。這使得價格低廉的學名藥得以進入市場。這種「專利懸崖」會大幅減少藥物研發公司的收入來源，並迫使它們承擔高昂的研發成本才能推出新藥。此外，嚴格的監管流程和進行臨床試驗所需的大量資金投入，也使新參與企業的商業化過程更加複雜。

市場促進因素

與生活方式相關的風險因素日益增多，是推動市場成長的主要動力。現代久坐的生活方式和環境因素加劇了心血管疾病的易感性。代謝紊亂，尤其是肥胖，會加速動脈粥狀硬化的進展，因此醫療保健提供者需要開立藥物進行預防和治療。根據美國心臟協會於2024年1月發布的《2024年心臟病和中風統計更新》，肥胖的流行顯著增加了心血管風險，約42%的美國成年人被歸類為肥胖。這種盛行率與缺血事件的發生率直接相關，因此需要持續的藥物治療。此外，環境因素也加重了疾病負擔。世界心臟聯盟於2024年5月發布的報告顯示，空氣污染每年導致約190萬人死於缺血性心臟疾病，凸顯了除了傳統的生活方式改變之外，還需要更多治療性介入。

同時，新型藥物療法和生物製藥的進步正在重塑治療框架，改變市場格局，並擴大市場獲利能力。Glucagon-Like Peptide-1(GLP-1) 受體促效劑在心血管領域的臨床成功，標誌著治療模式從傳統的症狀管理轉變為主動風險降低的重大轉變。根據諾和諾德公司於2024年3月發布的題為「Wegovy獲FDA核准用於降低心血管風險」的新聞稿，治療方法已被證實能顯著降低已確診心血管疾病成人患者發生主要心血管不利事件(MACE) 的風險達20%。這項監管突破不僅將拓展治療選擇，還將刺激製藥公司投資開發針對代謝和缺血通路的多方面治療方法，使更多患者群體受益。

市場挑戰

重磅藥物專利到期對全球缺血性心臟疾病（IHD）治療市場的收入成長構成重大阻礙。一旦關鍵藥物的獨家銷售權到期，市場將立即被生物等學名藥充斥。這些競爭產品通常比品牌藥便宜得多，並迅速侵蝕原廠藥的市場佔有率。因此，儘管由於疾病的高發病率，處方量持續成長，但隨著銷售轉向這些更具成本效益的替代藥物，整體市場價值面臨下行壓力。

醫療保健系統正積極推廣學名藥以遏制醫療成本飆升，而由此帶來的沉重財政負擔進一步加劇了這一趨勢。現有藥物的高價定價模式難以為繼，迫使製藥公司依賴高風險的創新來維持盈利。根據美國心臟協會預測，到2050年，美國與心血管疾病相關的直接和間接總成本預計將增加兩倍，達到約1.8兆美元（截至2024年）。日益成長的經濟負擔凸顯了關鍵的市場動態：支付方優先考慮削減開支，這加劇了專利到期帶來的影響，並限制了品牌缺血性心臟疾病治療藥物的獲利能力。

市場趨勢

隨著對標準他汀類藥物治療無效的高風險患者越來越重視積極的降脂治療，PCSK9抑制劑和生物目標的快速普及正在重塑市場格局。這一趨勢的特徵是siRNA療法和單株抗體的應用日益廣泛，它們能夠以更少的劑量強效且持久地降低低密度脂蛋白（LDL）水平。因此，隨著醫療系統將缺血性疾病的二級預防工具列為優先事項，製藥開發商從這些先進的注射劑中獲得了顯著的收入成長。根據諾華公司於2024年10月發布的2024年第三季財報，其siRNA療法RecVio的季度銷售額為1.98億美元，年增119%，凸顯了這些標靶治療的快速市場滲透。

同時，精準醫療的引進正在推動新型療法的研發，以降低由基因決定的心血管風險，特別是高脂蛋白（α）水平。與傳統的膽固醇管理不同，這種方法利用基因譜分析來識別具有傳統藥物無法解決的遺傳易感性的患者，從而促進了RNA干擾療法的研發。基因靜默劑的最新進展也支持了這種向個人化醫療的轉變，這些藥物能夠有效降低致病性脂蛋白的濃度。根據Silence Therapeutics公司於2024年11月發布的題為「Silence Therapeutics公佈Zerlasiran最新二期臨床試驗數據」的新聞稿，在臨床實驗藥物zerlasiran在36週內使已確診心血管疾病患者的平均脂蛋白（α）水平降低了80%以上，證明了精準醫療方法的有效性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球缺血性心臟疾病（IHD）治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病分類（心絞痛、心肌梗塞）
    • 藥物分類（血脂異常症治療藥物、鈣通道阻斷劑、 BETA阻斷劑、ACE抑制劑、ARB類藥物、血管擴張劑、抗血栓藥物）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美缺血性心臟疾病（IHD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲缺血性心臟疾病（IHD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區缺血性心臟疾病（IHD）治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲缺血性心臟疾病（IHD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲缺血性心臟疾病（IHD）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球缺血性心臟疾病（IHD）治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20007

The Global Ischemic Heart Disease (IHD) Drugs Market is projected to expand from a valuation of USD 6.23 Billion in 2025 to USD 7.98 Billion by 2031, progressing at a compound annual growth rate (CAGR) of 4.21%. These pharmaceutical agents are essential for managing conditions defined by restricted blood supply to the heart muscle, such as myocardial infarction and angina pectoris. The market's upward trajectory is fundamentally underpinned by an aging global population and the increasing prevalence of lifestyle-related comorbidities, including obesity and diabetes, which necessitate long-term pharmacological management. Data from the American College of Cardiology in 2023 indicates that ischemic heart disease affects approximately 240 million people globally, creating an urgent and sustained demand for effective therapeutic interventions across international markets.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.23 Billion
Market Size 2031USD 7.98 Billion
CAGR 2026-20314.21%
Fastest Growing SegmentAngina Pectoris
Largest MarketNorth America

A significant barrier potentially hindering market expansion is the expiration of patents for major blockbuster therapies, which allows for the entry of cost-effective generic competitors. This "patent cliff" severely diminishes revenue streams for originator pharmaceutical companies, compelling them to navigate high development costs to introduce novel drugs. Furthermore, the commercialization process for new market entrants is complicated by stringent regulatory pathways and the immense financial investment required to conduct clinical trials.

Market Driver

The escalation of lifestyle-related risk factors serves as a primary engine for market growth, as modern sedentary behaviors and environmental conditions worsen cardiovascular vulnerabilities. Metabolic disorders, particularly obesity, accelerate the progression of atherosclerosis, compelling healthcare providers to prescribe preventative and management pharmacotherapies. According to the American Heart Association's "2024 Heart Disease and Stroke Statistics Update" from January 2024, the obesity epidemic significantly contributes to cardiovascular risk, with nearly 42% of the U.S. adult population classified as obese. This prevalence directly correlates with the incidence of ischemic events, necessitating sustained drug regimens. Additionally, environmental factors contribute to the disease burden; the World Heart Federation reported in May 2024 that ambient air pollution caused approximately 1.9 million deaths specifically from ischemic heart disease in a single year, highlighting the expanding need for therapeutic interventions beyond traditional lifestyle modifications.

Simultaneously, advancements in novel drug therapies and biologics are redefining the treatment landscape and expanding the market's revenue potential. The recent clinical success of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular applications marks a significant evolution from traditional symptom management to proactive risk reduction. According to a March 2024 press release by Novo Nordisk titled "Wegovy receives FDA approval for cardiovascular risk reduction," the treatment demonstrated a statistically significant 20% reduction in the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease. This regulatory milestone not only broadens the therapeutic arsenal but also incentivizes pharmaceutical investment in developing multi-modal treatments that address both metabolic and ischemic pathways, thereby capturing a larger share of the patient population.

Market Challenge

The expiration of patents for major blockbuster therapies constitutes a formidable barrier to revenue growth within the Global Ischemic Heart Disease (IHD) Drugs Market. When exclusive marketing rights for leading pharmaceutical agents conclude, the market witnesses an immediate influx of bioequivalent generic formulations. These competitors are typically priced significantly lower than their branded counterparts, leading to a rapid erosion of market share for originator companies. Consequently, despite a sustained or increasing volume of prescriptions due to high disease prevalence, the overall monetary value of the market faces downward pressure as sales shift toward these cost-effective alternatives.

This trend is further exacerbated by the intense financial strain on healthcare systems, which aggressively promote the adoption of generic medicines to mitigate soaring healthcare expenditures. The inability to maintain premium pricing models for established drugs forces pharmaceutical developers to rely heavily on new, high-risk innovations to sustain profitability. According to the American Heart Association, in 2024, the total direct and indirect costs related to cardiovascular disease in the United States were projected to triple to approximately $1.8 trillion by 2050. This escalating economic burden underscores the critical market dynamic where payers prioritize reduced spending, thereby amplifying the impact of patent cliffs and restricting the revenue potential for branded ischemic heart disease therapies.

Market Trends

The accelerated adoption of PCSK9 inhibitors and targeted biologics is reshaping the market by addressing the critical need for aggressive lipid lowering in high-risk patients unresponsive to standard statin regimens. This trend is characterized by the increasing uptake of small interfering RNA therapies and monoclonal antibodies that offer potent, sustained low-density lipoprotein reduction with infrequent dosing schedules. Consequently, pharmaceutical developers are witnessing substantial revenue growth from these advanced injectables as healthcare systems prioritize secondary prevention tools for ischemic conditions. According to Novartis's "Q3 2024 Results" from October 2024, the company's siRNA therapy, Leqvio, recorded sales of $198 million for the quarter, representing a 119% increase compared to the previous year, highlighting the rapid market penetration of these targeted interventions.

Simultaneously, the implementation of precision medicine is driving the development of novel therapeutics designed to mitigate genetically determined cardiovascular risks, specifically elevated Lipoprotein(a). Unlike traditional cholesterol management, this approach utilizes genetic profiling to identify patients with inherited vulnerabilities that remain unaddressed by conventional drugs, fostering a new pipeline of RNA-interference therapies. This shift towards personalized care is evidenced by recent clinical advancements in gene-silencing agents that effectively reduce pathogenic lipoprotein concentrations. According to a November 2024 press release by Silence Therapeutics titled "Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data," the investigational drug zerlasiran demonstrated a time-averaged reduction in Lipoprotein(a) of more than 80% over 36 weeks in patients with established cardiovascular disease, validating the efficacy of these precision modalities.

Key Market Players

  • Bayer AG
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Actelion Pharmaceuticals Ltd.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG

Report Scope

In this report, the Global Ischemic Heart Disease (IHD) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ischemic Heart Disease (IHD) Drugs Market, By Disease Class

  • Angina Pectoris
  • Myocardial Infarction

Ischemic Heart Disease (IHD) Drugs Market, By Drug Class

  • Anti-Dyslipidemic Drugs
  • Calcium Channel Blockers
  • Beta-Blockers
  • ACE Inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic Agents

Ischemic Heart Disease (IHD) Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ischemic Heart Disease (IHD) Drugs Market.

Available Customizations:

Global Ischemic Heart Disease (IHD) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Class (Angina Pectoris, Myocardial Infarction)
    • 5.2.2. By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Class
    • 6.2.2. By Drug Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Class
        • 6.3.1.2.2. By Drug Class
    • 6.3.2. Canada Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Class
        • 6.3.2.2.2. By Drug Class
    • 6.3.3. Mexico Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Class
        • 6.3.3.2.2. By Drug Class

7. Europe Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Class
    • 7.2.2. By Drug Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Class
        • 7.3.1.2.2. By Drug Class
    • 7.3.2. France Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Class
        • 7.3.2.2.2. By Drug Class
    • 7.3.3. United Kingdom Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Class
        • 7.3.3.2.2. By Drug Class
    • 7.3.4. Italy Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Class
        • 7.3.4.2.2. By Drug Class
    • 7.3.5. Spain Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Class
        • 7.3.5.2.2. By Drug Class

8. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Class
    • 8.2.2. By Drug Class
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Class
        • 8.3.1.2.2. By Drug Class
    • 8.3.2. India Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Class
        • 8.3.2.2.2. By Drug Class
    • 8.3.3. Japan Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Class
        • 8.3.3.2.2. By Drug Class
    • 8.3.4. South Korea Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Class
        • 8.3.4.2.2. By Drug Class
    • 8.3.5. Australia Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Class
        • 8.3.5.2.2. By Drug Class

9. Middle East & Africa Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Class
    • 9.2.2. By Drug Class
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Class
        • 9.3.1.2.2. By Drug Class
    • 9.3.2. UAE Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Class
        • 9.3.2.2.2. By Drug Class
    • 9.3.3. South Africa Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Class
        • 9.3.3.2.2. By Drug Class

10. South America Ischemic Heart Disease (IHD) Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Class
    • 10.2.2. By Drug Class
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Class
        • 10.3.1.2.2. By Drug Class
    • 10.3.2. Colombia Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Class
        • 10.3.2.2.2. By Drug Class
    • 10.3.3. Argentina Ischemic Heart Disease (IHD) Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Class
        • 10.3.3.2.2. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Ischemic Heart Disease (IHD) Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly and Company
  • 15.3. Novartis International AG
  • 15.4. Pfizer, Inc.
  • 15.5. Sanofi S.A.
  • 15.6. Actelion Pharmaceuticals Ltd.
  • 15.7. Baxter International Inc.
  • 15.8. Boehringer Ingelheim International GmbH
  • 15.9. Bristol-Myers Squibb Company
  • 15.10. F. Hoffmann-La Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer